Integrin alpha1beta1

Integrin alpha1beta1 functions as a receptor for LAMININ and COLLAGEN. It is widely expressed during development, but in the adult is the predominant laminin receptor (RECEPTORS, LAMININ) in mature SMOOTH MUSCLE CELLS, where it is important for maintenance of the differentiated phenotype of these cells. Integrin alpha1beta1 is also found in LYMPHOCYTES and microvascular endothelial cells, and may play a role in angiogenesis. In SCHWANN CELLS and neural crest cells, it is involved in cell migration. Integrin alpha1beta1 is also known as VLA-1 and CD49a-CD29.

Also Known As:

Networked: 86 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Pozzi, Ambra: 6 articles (11/2008 - 08/2004)
2.	Marcinkiewicz, Cezary: 4 articles (12/2015 - 05/2003)
3.	Topham, David J: 4 articles (10/2014 - 02/2004)
4.	Gardner, Humphrey: 4 articles (07/2007 - 03/2002)
5.	de Fougerolles, Antonin R: 4 articles (06/2007 - 12/2002)
6.	Cosgrove, Dominic: 3 articles (11/2010 - 08/2004)
7.	Tuszynski, George P: 3 articles (08/2009 - 05/2003)
8.	Zent, Roy: 3 articles (10/2008 - 08/2004)
9.	Chen, Xiwu: 3 articles (08/2008 - 08/2004)
10.	Bank, Ilan: 3 articles (11/2004 - 05/2002)

Related Diseases

1.	Human Influenza (Influenza) 04/01/2010 - "We investigated the role of VLA-1 on virus-specific CD4(+) T cells during and after primary or secondary influenza infection of mice. " 10/01/2014 - "In addition, a significant proportion of X31-sciIV-induced antigen-specific respiratory CD8 T cells expressed VLA-1, a marker that is associated with heterologous influenza protection. " 04/01/2010 - "Identification of a unique population of tissue-memory CD4+ T cells in the airways after influenza infection that is dependent on the integrin VLA-1." 10/15/2007 - "The alpha1beta1 integrin and TNF receptor II protect airway CD8+ effector T cells from apoptosis during influenza infection." 02/01/2004 - "Our studies show that the collagen binding alpha1beta1 integrin, VLA-1, is expressed by the majority of influenza-specific CD8 T cells recovered from nonlymphoid tissues during both the acute and memory phases of the response. "
2.	Infections 10/15/2007 - "We propose that TNFR-II and the VLA-1 synergize to protect effector CD8 T cells in the infected airways from apoptosis during the acute infection." 04/01/2010 - "We investigated the role of VLA-1 on virus-specific CD4(+) T cells during and after primary or secondary influenza infection of mice. " 04/01/2006 - "Regarding a functional role of VLA-1, we found that intracerebral infection of both VLA-1(-/-) and wild-type (wt) mice resulted in lethal T-cell-mediated meningitis, and quantitative and qualitative analyses of the cellular exudate did not reveal any significant differences between the two strains. " 09/01/2008 - "Here, we examined if alpha1beta1 integrin is required in the development and maintenance of the granulomatous structure during pulmonary infection using the alpha1 integrin knockout (alpha1-null) mouse. " 04/01/2006 - "Taken together, the current findings indicate that the expression of VLA-1 is not pivotal for T-cell-mediated antiviral immunity to a systemic infection."
3.	Lung Neoplasms (Lung Cancer) 08/01/2008 - "Loss of integrin alpha1beta1 ameliorates Kras-induced lung cancer." 08/01/2008 - "The collagen IV binding receptor integrin alpha1beta1 has been shown to regulate lung cancer due to its proangiogenic properties; however, it is unclear whether this receptor also plays a direct role in promoting primary lung tumors. "
4.	Neoplasms (Cancer) 01/01/2016 - "In addition, in vivo blockade of either VLA-1 or CD103 significantly impaired control of subcutaneous tumors. " 02/01/1992 - "The rIL-2 infusion induced migration of leukocytes to the tumors, which was related to increased expression of the adhesion molecule VLA-1 on both peripheral blood mononuclear cells and the endothelial cells of small tumor vessels. " 08/01/1989 - "In this study we found that rIL-2 activation and culture of ICL generates killer activity against NK-resistant and fresh tumor targets and that enrichment in expression of NKH1, CD8, and VLA-1 antigens is associated with effector function." 11/01/2008 - "Characterization of the anti-angiogenic properties of arresten, an alpha1beta1 integrin-dependent collagen-derived tumor suppressor." 05/01/2003 - "Importantly, obtustatin potently inhibited angiogenesis in vivo in the chicken chorioallantoic membrane assay, and in the Lewis lung syngeneic mouse model, it reduced tumor development by half, confirming and extending previous results on the relevance of alpha1beta1 integrin to angiogenesis and suggesting novel approaches to the generation of angiogenesis inhibitors."
5.	Cicatrix (Scar) 10/01/2002 - "Treatment with an antibody to VLA-1 integrin reduces glomerular and tubulointerstitial scarring in a rat model of crescentic glomerulonephritis." 04/01/1999 - "To clarify molecular and cellular mechanisms involved in abnormal mesangial remodeling, this study focused on the role of alpha1beta1 integrin, a collagen/laminin receptor, in rat mesangial cells, using collagen gel contraction as an experimental model of in vivo collagen matrix remodeling and scar formation. " 09/01/2002 - "alpha1beta1 integrin is a potential collagen-binding extracellular matrix receptor that mediates collagen-dependent cell adhesion, proliferation, migration, and collagen matrix assembly and thereby may participate in the wound healing and pathologic scarring observed in some damaged organs. " 10/01/2002 - "We conclude that VLA-1 mediates both glomerular and interstitial fibrosis in crescentic glomerulonephritis and that neutralization of VLA-1, which enhanced expression of matrix metalloproteinase-9, is a possible therapeutic strategy in progressive renal scarring."

Related Drugs and Biologics

1.	Integrin alpha1beta1
2.	Collagen
3.	Antigens
4.	Laminin Receptors
5.	Integrins
6.	Integrin alpha2beta1
7.	Integrin alpha6beta1
8.	Integrin alpha3beta1
9.	Integrin alpha4beta1 (VLA-4)
10.	Collagen Receptors

Related Therapies and Procedures

1.	Therapeutics